While SnCE1 was reported to act as an efficient deSUMOylase with weak DUB activity, for SnCE2-5 no activity neither as DUB, ULP nor reaction with activity-based probes, i.e., ubiquitin-propargylamide (Ub-PA), SUMO1-PA, SUMO3-PA, ISG15-PA or NEDD8-PA was observed 26,57
The promises and limitations of N- acetylcysteine as a potentiator of first-line and second-line tuberculosis drugs
This short, aggressive cycle is designed to maximize anabolic stimulus while minimizing risks from prolonged IGF-1 elevation
Eur J Cell Biol
Depending on your health history and unique goals, a clinician can determine which prescription medication is right for you
The aim is to separate promising ideas from treatments that have been properly tested in humans, especially when Crohns disease or ulcerative colitis may be active